Bret Jensen is a Financial Blogger and Contributor at Model Portfolio. He covers a diverse range of topics including finance, trading, and healthcare, with a particular focus on markets, biotech, the Federal Reserve, AI, and the FDA. Bret's insights and analyses have been featured in TheStreet and Seeking Alpha.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Bret Jensen's articles predominantly cover investment analysis in the healthcare, pharmaceutical, and biotechnology sectors. He frequently cites data to support his analysis. To effectively reach out to Bret, provide well-researched insights or expert commentary on companies within the pharmaceutical and biotech industries that are backed by solid data and financial analysis.
Given his focus on stock market coverage within these sectors, pitches should be tailored to appeal to investors seeking detailed financial and industry-specific insights into pharmaceuticals, biotechnology, and medical technology companies. Although Bret doesn't have a specific geographic focus mentioned, it would be beneficial for sources with international perspectives or those impacting global markets to engage him effectively.
This information evolves through artificial intelligence and human feedback. Improve this profile .
These big name stocks might be surprising picks, until you ask: Could things really get any worse for them?
CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising Phase 3 data for Cretostimogene. Learn more on CGON stock here.
Discover three oversold biotech/biopharma stocks to watch amidst market volatility and the JP Morgan Healthcare event in San Francisco. Read up on our picks on Seeking Alpha.
By: Bret Jensen
Dianthus Therapeutics is advancing treatments for autoimmune diseases. Read why DNTH stock is receiving Buy ratings and price targets of $40 to $58.
Predicting what a new administration might mean for the economy and the markets.
Hologic is down approximately 20% from recent highs and continues to grow organically and via a series of 'bolt-on' acquisitions. Learn more on HOLX stock here.
This is my strategy with this reasonably priced healthcare stock in an overbought market.
(833) 317-6278 
